Evaluation of Fludarabine Phosphate in Patients with Recurrent Glioma

No abstract is available for this paper.

• Publication year

  1988

• Venue

  American Journal of Clinical Oncology

• Publication date

  1988-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00000421-198810000-00015PMID 2459951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.

  1986cited by this paper
• Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.

  1986cited by this paper
• Central nervous system toxicity of fludarabine phosphate.

  1986cited by this paper
• Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

  1984cited by this paper
• One-sample multiple testing procedure for phase II clinical trials.

  1982cited by this paper
• Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.

  1980cited by this paper

• Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors

  2024cites this paper
• Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

  2022cites this paper
• Fludarabine phosphate

  2020cites this paper
• The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

  2007cites this paper
• New agents in the treatment of primary brain tumors

  2005cites this paper
• Chemotherapy for high-grade gliomas

  2000cites this paper
• Chemotherapy for adults with malignant glioma.

  1999cites this paper
• Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine

  1996cites this paper
• The role of chemotherapy in recurrent malignant gliomas: an overview.

  1996cites this paper
• Infectious and immunosuppressive complications of purine analog therapy.

  1995cites this paper
• Innovative Antimetabolites in Solid Tumours

  1994cites this paper
• Neurotoxicity of purine analogs: a review.

  1994cites this paper
• Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

  1994cites this paper
• A Review of Fludarabine and Cladribine in Solid Tumours

  1994cites this paper
• Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

  1993cites this paper
• Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

  1992cites this paper
• Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.

  1991cites this paper
• Neuro-oncology index and review (adult primary brain tumors)

  1991cites this paper
• Fludarabine: A Review

  1991cites this paper
• Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

  1990cites this paper
• The role of chemotherapy in the treatment of gliomas in adults.

  1989cites this paper